Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Collagen Corp./Biomatrix

This article was originally published in The Gray Sheet

Executive Summary

Collagen Corp./Biomatrix: Collagen Corp. pays Biomatrix $5 mil. for rights to market Hylaform -- "a hylan gel used for viscoaugmentation of dermal tissue to correct facial wrinkles and depressed scars" -- in Europe, Japan, Australia, Canada, "and select other countries." Collagen also gains rights to market Hylaform in the U.S. following FDA marketing approval; a premarket approval application for the hylan gel was accepted for filing by the agency in October ("The Gray Sheet" Oct. 2, 1995, In Brief)...



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts